

Log In

- Go to the SciFinderⁿ Log In page: <https://scifinder-n.cas.org>
- Log In using your existing SciFinder username and password.
 - First-time commercial users may self-register.

Search SciFinderⁿ: SciFinderⁿ features a streamlined search interface.

References: The References display features visualizations, dynamic facets and an easy-to-use layout.

- References are ranked and sorted by Relevance to determine Best, Good and Fair collections.
- Full text acquisition options are available on the reference page
- You may Save your Searches and set-up Alerts.

- Click on the Reference Title (see the image above) to view the Reference's record details including bibliographic information, publication history, indexing, graphs and more.

Go to References screen.

Retrieve data for reference.

Access an interactive version of the patent PDF that highlights the specific location of indexed substances.

View previous or next reference.

Access map of references this document cites, and references that cite this document.

Download, email, or save reference.

Access other full-text options.

PDF displays original patent PDF. PDF+ displays patent PDF with table of important chemistry. Viewer displays interactive version of PDF in PatentPak Viewer.

Click to view patent family member on Reference Detail screen.

Expand to view concepts that characterize the general subject matter of the document.

Expand to view substances associated with document.

Expand to view citations from this document.

Reference Detail (5 of 4,015)

Substances (12) Reactions (0) Cited By (1) PATENTPAK Viewer Citation Map

Patent

Patent Information

Patent Number
WO2015058034

Publication Date
2015-04-23

Application Number
WO2014-US61038

Application Date
2014-10-17

Kind Code
A1

Assignee
The Regents of the University of Colorado, A Body Corporate, United States

Source
World Intellectual Property Organization

Database Information
AN: 2015:690500
CAN: 162:544597
CAplus

Language
English

Use of tyrosine kinase inhibitor in cancer treatment

By: Reyland, Mary E.; Wie, Sten; Degregori, James

Abstract: The invention provides methods for reducing apoptosis of non-cancerous cells during a cancer treatment and beneficial effects associated with reducing such apoptosis. In particular, methods of the invention comprise administering a tyrosine kinase inhibitor to a cancer patient who is undergoing cancer treatment in order to reduce apoptosis of non-cancerous cells. In another aspect of the invention the tyrosine kinase inhibitor is selected from the group consisting of dasatinib, imatinib, ponatinib, saracatinib, and a combination thereof.

A

0 hr 1 hr 4 hr 30 Days 60 Days 90 Days
+TKI +IR +TKI Collect Saliva Collect Saliva Collect Saliva

B

Saliva Flow / Weight

Days Following Radiation

Control Dasatinib IR IR + Dasatinib

C

Saliva Flow / Weight

Days Following Radiation

Control Imatinib IR IR + Imatinib

D

Saliva Flow / Weight

Days Following Radiation

Control Bosutinib IR IR + Bosutinib

Full Text

Patent Family

Patent	Language	Kind Code	PatentPak Options	Publication Date	Application Number	Application Date
WO2015058034	English	A1	PDF PDF+ Viewer	2015-04-23	WO2014-US61038	2014-10-17
		P			US2013-61893132P	2013-10-18
US20160228436	English	A1	PDF	2016-08-11	US2016-1515029617	2016-04-14

Expand All | Collapse All

Concepts

Substances

Citations (2)

Substances (12)

Expand All | Collapse All

Substance Role: Pharmacological Activity (7)

943319-70-8
C20H27N5O
Benzamide, 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl-...
PatentPak

380843-75-4
C20H22Cl2N4O3
3-Quinolincarbonitrile, 4-[[2,4-dichloro-5-methox...
PatentPak

379231-04-6
C22H22ClN4O3
4-Quinazolinamine, N-(5-chloro-1,3-benzodioxol-4-yl-...
PatentPak

Substance Role: Therapeutic Use (7)

● **Substances:** A Substance search returns results in an intuitive layout. The display highlights most relevant hits, critical property information and high-resolution images of structures.

- Click on View Detail to display the Substance's record detail.

Retrieve data related to answers. Download answers to an external file. Change how answers are displayed.

Select type of structure match. Select filters to focus answers.

Go to Substance Detail screen. View Key Physical Properties on Substance Detail screen.

Share answers by emailing link. Save answers.

Retrieve data for substance.

View Full

Substances (6)

Structure Match

As Drawn (1)

Substructure (6)

Similarity (3,437)

Filter by

Commercial Availability

Available (1)

Not Available (5)

Reaction Role

Product (2)

Reactant (4)

Reference Role

Biological Study (1)

Preparation (2)

Prophetic in Patents (1)

Reactant or Reagent (4)

Uses (1)

Number of Components

Substance Class

Molecular Weight

1219937-98-0

View Detail

Key Physical Properties

Property	Value	Condition
Molecular Weight	404.4±30.0	Press: 760 Torr
Boiling Point (Predicted)	404.4±30.0 °C	
Density (Predicted)	1.504±0.06 g/cm ³	Temp: 20 °C; Press: 760 Torr
pKa (Predicted)	13.86±0.70	Most Acidic Temp: 25 °C

C₁₁H₉ClFNO₂

Cyclopropanecarbonyl chloride, 1-[[[4-fluorophenyl]amino]carbonyl]-

29 References 98 Reactions 1 Supplier

1416321-38-4

View Detail

Key Physical Properties

Property	Value	Condition
Molecular Weight	276.09	-
Boiling Point (Predicted)	428.6±45.0 °C	Press: 760 Torr
Density (Predicted)	1.600±0.06 g/cm ³	Temp: 20 °C; Press: 760 Torr
pKa (Predicted)	13.18±0.70	Most Acidic Temp: 25 °C

C₁₁H₈Cl₂FNO₂

Cyclopropanecarbonyl chloride, 1-[[[3-chloro-4-fluorophenyl]amino]carbonyl]-

1 Reference 2 Reactions 0 Suppliers

● **Reactions:** A Reaction Search displays relevant Reaction Schemes. A Scheme contains reactions with the same Reagents and Products.

- Expand the Scheme, and click View Reaction Detail to details of the reaction.

Go to Reactions screen. View previous or next reaction.

Download answers to an external file. Share answers by emailing link. Save data.

Click any substance image or name to display substance menu. Use menu options to view substance details (CAS Registry Number), zoom image (magnifier), retrieve associated information (Reactions, Suppliers, References), or copy substance to editor (Edit Substance).

Retrieve suppliers for substance.

View reaction reference on Reference Detail screen.

View full-text PDF for the patent reference or Patent Family members.

Access other full-text options.

Return to All Reaction Schemes

Reaction Detail (Scheme 1, Reaction 2 of 20)

Suppliers (2) Suppliers (25) Suppliers (55)

Step 1

Stage	Reagents	Catalysts	Solvents	Conditions
1	Potassium carbonate	-	Tetrahydrofuran Water	10 min, > 30 °C
2	Water	-	-	10 h, 15 - 30 °C

CAS Reaction Number 31-365-CAS-4160897

Notes

alternative reaction conditions shown

Experimental Protocols

Experimental Procedure

Preparation of N-(4-((6,7-bis(methoxyquinolin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

The solution from the previous step containing 1-(4-fluoro-phenyl)carbamoyl-cyclopropanecarbonyl chloride was added to a mixture of 4-(6,7-dimethoxy-quinoline-4-yloxy)phenylamine (3.0 kg), and potassium carbonate (4.0 kg) in THF (27.0 kg), and water (13.0 kg) at a rate such that the hatch temperature did not exceed 3.0 °C. When the reaction was complete (approximately 10 minutes), water (74.0 kg) was added. The mixture was stirred at 15 to 300 °C for approximately 10 hours, which resulted in the precipitation of the product. The product was recovered by filtration, washed with a pre made solution of THF (11.0 kg) and water (24.0 kg), and dried at approximately 659 °C under vacuum for approximately 12 hours to afford the title compound. Yield (free base, 5.0 kg). ¹H NMR (400 MHz, d₂-DMSO): δ 10.2 (s, 1 H), 10.05 (s, 1H), 8.4 (s, 1H), 7.8 (m, 2H), 7.65 (m, 2H), 7.5 (s, 1H), 7.35 (s, 1H), 7.25 (m, 2H), 7.15 (m, 2H), 6.4 (s, 1H), 4.0 (d, 6H), 1.5 (s, 4H) LC/MS: M+H = 502.

Reference

Method of treating cancer and bone cancer pain

By: Schwab, Gisela; et al

World Intellectual Property Organization, WO2012151326 A1 2012-11-08

PATENTPAK Full Text

Patent Information

Patent Number WO2012151326

Publication 2012-11-08

Application Number WO2012-US36191

Application Date 2012-05-02

Kind Code A1

Assignee Exelixis, Inc., United States

